KOUL ANIL,YSEBAERT NINA,ROYMANS DIRK ANDRÉ E.,GOEYVAERTS NELE ISA E.
申请号：
CL2019001455
公开号：
CL2019001455A1
申请日:
2019.05.29
申请国别(地区):
CL
年份:
2019
代理人:
摘要：
<；p>； The present invention relates to the combination of the compound to the inhibitor of vsr, that is, 3 - ({5- chloro-l- [3- (methisis! fonil) propyl] -l / findol- 2-yl} metii) -l- (2,2,2-trifluoroethyl) -l, 3-dihldro-2w-imldazo [4,5ldquo； cjpiridin-z-one, and one or more compounds b vsr inhibitor compounds selected from ribavirin, gs-5806, mdt-637, bta-9881, bms-433771, ym-543403, a-60444, tmc-353121, rfi -641, cl-387626, mbx-300, a2-27, medi8897, cr95 (31, palivizumab, 3 - ({5-chloro-l- [3- (methylsulfonyl) propyl] -17fbenzimidazol-2- yl} methyl) -l-cyclopropyl-l, 3-dihydro-2 ^ imidazo [4,5-c] pyridin-2-one,- 1-2-4) phenyl 1-1-2-2-2-phenyl-benzene (6) bis (5) phenyl ampere； [35；] 39； - benzene 2O [ iquest； J] tieno [2, 3-O] azepino-2-carboxamida, and 4-amino-8 - [3 - [[2 - (3], Am amp； Iacute； no] - 6, 6-dimetyl-2 - (4-MET ~ 3-nitrofenil) - 3 / fimidazo [4.5 / / 7] isoquinlino-7.9 (6m8 / ~ Diona) for the treatment or improvement of infacci amp； oacute； n VSR. Invention and ampere； oacute； n refers to ADEM amp； Aacute； s refers to the combined product of compound A and one or one M amp； Aacute； s compound B,a pharmaceutical product comprising the compound a and one or more compounds b, the use of the combination of the compound a and one or more compounds b (or the pharmaceutical product comprising the compound a and one or more) ； s compounds b) for the treatment of infection by the VSR, and a method to treat or improve infection by the VSR in a subject in need that comprises administering the combination of compound a and one or maacute； s compounds b in an effective amount to said subject. <；/p>；<；p>；La presente invenció；n se refiere a la combinació；n del compuesto a inhibidor del vsr, es decir, 3-({5- cloro-l-[3-(metiisu!fonil)propil]-l/findol-2-il}metii)-l-(2,2,2-trifluoroetil)-l,3-dihldro-2w-imldazo[4,5&ldquo； cjpiridin-z-ona, y uno o má；s compuestos b inhibidores del vsr seleccionados entre ribavirina, gs-5806, mdt-637, b
